Iom Bioworks Raises ₹4 Crore in Seed Funding to Advance Personalised Gut Health Solutions

Iom Bioworks, a Bengaluru-based deep science company focused on microbiome-driven healthcare, has raised ₹4 crore in Seed Round funding led by Inflection Point Ventures (IPV). The funds will be used to expand customer outreach, strengthen infrastructure, secure intellectual property rights, and grow both its scientific and commercial teams.

Founded in 2022, Iom Bioworks personalises health by identifying key bacteria in the gut and modulating them to support overall well-being. The company’s patented platform combines biological network theory, mathematical modelling, nutritional science, and artificial intelligence to provide personalised food and prebiotic recommendations. These services are delivered to customers across India through at-home gut profiling kits and a fully digital experience.

In its first year of operations, Iom Bioworks served over 500 customers. The company has secured two patents with two more in advanced stages and has published several papers in the fields of microbiome science and computational biology. Its operations are supported by Pan-India logistics and a digital-first approach.

The leadership team includes Bipin Pradeep Kumar, Co-Founder and CEO, who integrates microbiome science with technology and customer focus; Dr. Samik Ghosh, Co-Founder and Chief of Science & Technology, who works at the intersection of computation and biology to create health-focused solutions; and Dr. Hiroaki Kitano, Co-Founder and Chief of Research & Collaboration, a systems biologist and AI specialist with decades of experience in robotics and scientific discovery.

Inflection Point Ventures has so far invested over ₹800 crore across 210+ startups. With this investment in Iom Bioworks, the firm aims to support advancements in microbiome science as a step towards preventive and personalised healthcare.

According to current forecasts, the global market for health tests, wellness platforms, and subscriptions is expected to grow at a compound annual growth rate (CAGR) of 28%, reaching USD 900 billion by 2030. With a science-backed platform, Iom Bioworks plans to contribute to this shift by offering accessible, personalised gut health solutions.